Compare CDMOs in the Gulf Cooperation Council (GCC) region. Filter by manufacturing type, regulatory approvals, and government-backed capacity expansion programs.
The Gulf Cooperation Council (GCC) states -- Saudi Arabia, UAE, Qatar, Kuwait, Bahrain, and Oman -- are collectively investing billions in domestic pharmaceutical manufacturing as part of economic diversification strategies. Saudi Vision 2030 and UAE Industrial Strategy 2031 both target significant increases in locally manufactured pharmaceuticals.
The GCC pharmaceutical market exceeds $15 billion annually and is growing at 5-7% per year. Currently, the region imports over 80% of its pharmaceuticals. Government mandates for local manufacturing content, combined with public procurement preferences for domestically produced drugs, create strong commercial incentives for CDMO establishment.
Infrastructure is a GCC advantage. New pharmaceutical manufacturing zones in Saudi Arabia (MODON industrial cities), UAE (Abu Dhabi and Dubai industrial zones), and Qatar offer modern utilities, streamlined permitting, and proximity to international logistics hubs. The challenge is workforce development -- CDMOs must invest in training programs as the region builds pharmaceutical manufacturing expertise.
No companies found in this category yet. Check back soon.
Browse all CDMOsOur AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.